Jefferies Group

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Retrieved on:

목요일, 5월 9, 2024

Type 1 diabetes, Lupus, Jefferies Group, Acquisition, Sclerosis, Multiple sclerosis, BLA, Immune system, Music

ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.

Key Points:

ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
Frexalimab is in three Phase 3 clinical studies for the treatment of multiple sclerosis (MS).
Sanofi stated that potential non-risk-adjusted peak sales for frexalimab may be greater than €5 billion (December 7, 2023 R&D Day).
Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.

AGS Enters Into Definitive Agreement To Be Acquired By Brightstar Capital Partners for Approximately $1.1 Billion

Retrieved on:

목요일, 5월 9, 2024

Citizenship, LLP, EDT, Investment, Macquarie Group, Barclays, Kirkland & Ellis, Culture, JMP, Jefferies Group, Cooley LLP, AGS, Cryptocurrency

The Company’s Board of Directors has unanimously approved, and recommended that the Company's stockholders approve, the agreement.

Key Points:

The Company’s Board of Directors has unanimously approved, and recommended that the Company's stockholders approve, the agreement.
AGS is a global company focused on creating a diverse mix of entertaining gaming experiences for every kind of player.
Joining forces with Brightstar represents an exciting new chapter for AGS and our mission to provide exceptional gaming solutions for our operator partners,” said David Lopez, CEO & President of AGS.
Upon completion of the transaction, AGS will become a privately held company and shares of AGS common stock will no longer be listed on any public market.

Skyward Specialty Announces Pricing of Its Secondary Offering of Its Common Stock

Retrieved on:

화요일, 5월 7, 2024

4th floor, Sale, Prospectus, Keefe, Bruyette & Woods, Broadridge Financial Solutions, Security (finance), Jefferies, Barclays, Form S-3, Madison Avenue, TD Securities, Form, Exercise, JMP, Jefferies Group, Equity capital markets, Attention, Telephone

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced the pricing of its secondary offering of 4,400,000 shares being offered by The Westaim Corporation, through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) at $36.50.

Key Points:

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced the pricing of its secondary offering of 4,400,000 shares being offered by The Westaim Corporation, through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) at $36.50.
In connection with the offering, the Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of Skyward Specialty's common stock.
The Selling Stockholder will hold 4.80% and 6.45% in Skyward Specialty, assuming full and no exercise of the underwriters’ option to purchase the additional shares, respectively.
Barclays, Keefe, Bruyette & Woods, Inc., A Stifel Company, and Jefferies are acting as joint lead book-running managers for the proposed offering.

Skyward Specialty Announces Secondary Offering of Its Common Stock

Retrieved on:

월요일, 5월 6, 2024

4th floor, Sale, Prospectus, Keefe, Bruyette & Woods, Broadridge Financial Solutions, Security (finance), Jefferies, Barclays, Form S-3, Madison Avenue, Form, Exercise, Jefferies Group, Equity capital markets, Attention, Telephone

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced that The Westaim Corporation (“Westaim”), through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) is offering 4,400,000 shares of the Company’s common stock in an underwritten secondary public offering.

Key Points:

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced that The Westaim Corporation (“Westaim”), through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) is offering 4,400,000 shares of the Company’s common stock in an underwritten secondary public offering.
In connection with the offering, the Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of Skyward Specialty's common stock.
The Selling Stockholder will be a 4.80% and 6.45% shareholder in Skyward Specialty, assuming full and no exercise of the underwriters’ option to purchase the additional shares, respectively.
Skyward Specialty will not receive any of the proceeds from the sale of the shares of its common stock offered by the Selling Stockholder, and the Selling Stockholder will bear the underwriting discounts and commissions associated with the sale of such shares.

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

Retrieved on:

월요일, 5월 6, 2024

Sale, Prospectus, Capital market, Guggenheim Partners, Madison Avenue, Floor, ADC, Jefferies Group, Cantor, Marketing, Attention, Therapy, Telephone, SIX Swiss Exchange, Security (finance)

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price).

Key Points:

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price).
The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million.
The offering is expected to close on May 8, 2024, subject to customary closing conditions.
Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.

Silvaco Announces Pricing of Initial Public Offering

Retrieved on:

목요일, 5월 9, 2024

Silvaco Group, Inc. (“Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and AI through software and innovation, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $19.00 per share.

Key Points:

Silvaco Group, Inc. (“Silvaco”), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and AI through software and innovation, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $19.00 per share.
The aggregate gross proceeds to Silvaco from the offering are expected to be $114.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Silvaco.
In addition, Silvaco has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of Silvaco’s common stock from Silvaco at the public offering price, less underwriting discounts and commissions.
Needham & Company is acting as lead manager and Craig-Hallum Capital Group and Rosenblatt are acting as co-managers for the offering.

TPG Rise Climate to Acquire Olympus Terminals, Leading Renewable Fuels Logistics Provider

Retrieved on:

화요일, 5월 7, 2024

Other Transport, Environment, Maritime, Other Energy, Transport, Alternative Energy, Sustainability, Energy, Logistics, Supply Chain Management, Climate, TPG, Kirkland & Ellis, Growth, Davidson Kempner Capital Management, Jefferies Group, Port, Renewable energy

TPG Rise Climate, the dedicated climate investing strategy of TPG’s global impact investing platform TPG Rise, today announced that it has signed a definitive agreement to acquire Olympus Terminals (“Olympus”), a leading independent storage provider for renewable fuels and refined products in Southern California, majority owned by an affiliated investment fund of Davidson Kempner Capital Management LP and an affiliated investment fund of Intrepid Investment Management, LLC.

Key Points:

TPG Rise Climate, the dedicated climate investing strategy of TPG’s global impact investing platform TPG Rise, today announced that it has signed a definitive agreement to acquire Olympus Terminals (“Olympus”), a leading independent storage provider for renewable fuels and refined products in Southern California, majority owned by an affiliated investment fund of Davidson Kempner Capital Management LP and an affiliated investment fund of Intrepid Investment Management, LLC.
The transaction will advance TPG Rise Climate’s efforts to reduce transportation-related greenhouse gas emissions by facilitating the import, storage, and distribution of renewable fuels in Southern California and accelerating California’s transition from conventional diesel to renewable diesel (RD).
“Olympus’ assets and operations are central to the sustainable fuels ecosystem, and we look forward to partnering with their management team.”
The company’s assets play a key role in the renewable diesel value chain in California.
Jefferies LLC served as financial advisor and Kirkland & Ellis served as legal counsel to TPG.

KKR to Acquire Healthium from Apax Funds

Retrieved on:

월요일, 5월 6, 2024

KKR, a leading global investment firm, today announced the signing of definitive agreements under which funds managed by KKR will acquire Healthium Medtech Ltd. (“Healthium”), a leading Indian medical devices company, from an affiliate of Funds advised by Apax Partners LLP (“Apax”), a leading global private equity advisory firm.

Key Points:

KKR, a leading global investment firm, today announced the signing of definitive agreements under which funds managed by KKR will acquire Healthium Medtech Ltd. (“Healthium”), a leading Indian medical devices company, from an affiliate of Funds advised by Apax Partners LLP (“Apax”), a leading global private equity advisory firm.
The acquisition will be made by a special purpose vehicle owned by KKR-managed funds which will acquire a controlling interest in Healthium group, including Healthium.
The Apax Funds acquired Healthium in 2018 and transformed the company from a domestic suture player into a global medical devices leader.
Apax Partners and Healthium were advised by Jefferies LLC as financial advisor and Kirkland & Ellis LLP as legal counsel.

Games Global Announces Launch of IPO

Retrieved on:

목요일, 5월 2, 2024

Games Global Limited (“Games Global”), a leading developer, distributor and marketer of innovative online, casino-style gaming (“iGaming”) content and integrated business-to-business solutions to iGaming operators, announced today that it has launched the roadshow for its initial public offering (“IPO”) of 14,500,000 ordinary shares.

Key Points:

Games Global Limited (“Games Global”), a leading developer, distributor and marketer of innovative online, casino-style gaming (“iGaming”) content and integrated business-to-business solutions to iGaming operators, announced today that it has launched the roadshow for its initial public offering (“IPO”) of 14,500,000 ordinary shares.
The offering consists of 6,000,000 ordinary shares offered by Games Global and 8,500,000 ordinary shares to be sold by Games Global’s existing shareholder (the “Selling Shareholder”).
Games Global will not receive any proceeds from the sale of the shares by the Selling Shareholder.
Games Global has applied to list its ordinary shares on the New York Stock Exchange under the symbol "GGL".

S&P Global Announces Successful Completion of Visible Alpha Acquisition

Retrieved on:

수요일, 5월 1, 2024

Slate, Feed, LLP, Capital, SPGI, Research, Jefferies Group, S&P Global, Acquisition, Morgan, Lewis & Bockius, API, Overalls, Alpha, Cryptocurrency

NEW YORK, May 1, 2024 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the successful completion of its acquisition of Visible Alpha, the financial technology provider of deep industry and segment consensus data, creating a premium offering of fundamental investment research capabilities on S&P Global Market Intelligence's Capital IQ Pro platform.

Key Points:

NEW YORK, May 1, 2024 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the successful completion of its acquisition of Visible Alpha, the financial technology provider of deep industry and segment consensus data, creating a premium offering of fundamental investment research capabilities on S&P Global Market Intelligence's Capital IQ Pro platform.
Visible Alpha will be operated within the S&P Global Market Intelligence division.
"Visible Alpha and its innovative team are an outstanding complement to S&P Global's culture and capabilities," said Adam Kansler, President of S&P Global Market Intelligence.
S&P Global announced its agreement to acquire Visible Alpha in February 2024.